Literature DB >> 6861091

Acinic cell adenocarcinoma. A clinicopathologic analysis of 294 cases.

G L Ellis, R L Corio.   

Abstract

Two hundred and ninety-four cases of acinic cell adenocarcinoma were reviewed for the purpose of defining the clinical parameters and determining the distribution of the four histomorphologic tissue patterns and five cell types for correlation to biologic behavior. The vast majority occurred in the parotid gland. There was a male predominance and a peak incidence in the third decade of life. The tumors were usually less than 3 cm in diameter and were slow growing. Pain was a common symptom, but was not indicative of prognosis. Nearly one half of the neoplasms exhibited multiple tissue growth patterns, and three fourths of the tumors displayed more than one cell type. The microcystic pattern was seen most frequently, regardless of the biological behavior of the tumors. The well-differentiated acinic cell was the most prevalent cell type except in cases with metastases, where the intercalated-duct cell type was slightly more frequent. Follow-up of 244 cases revealed a recurrence rate of 12%, a metastatic rate of 7.8%, and death rate of 6.1%. Since all histomorphologic patterns and cell types were manifest in tumors which recurred, metastasized, or caused the death of the patients, it seems appropriate to consider these neoplasms as low-grade adenocarcinomas rather than essentially benign with occasional unpredictable malignant behavior.

Entities:  

Mesh:

Year:  1983        PMID: 6861091     DOI: 10.1002/1097-0142(19830801)52:3<542::aid-cncr2820520326>3.0.co;2-a

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  25 in total

Review 1.  Salivary acinic cell carcinoma: reappraisal and update.

Authors:  V Vander Poorten; A Triantafyllou; L D R Thompson; J Bishop; E Hauben; J Hunt; A Skalova; G Stenman; R P Takes; D R Gnepp; H Hellquist; B Wenig; D Bell; A Rinaldo; A Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-12-19       Impact factor: 2.503

2.  Papillary squamous cell carcinoma of antrum-clear cell variant.

Authors:  Sangeeta R Patankar; V Poornima; Vineet Avdhani; Sanya Bhatia
Journal:  J Oral Maxillofac Pathol       Date:  2014-01

3.  Most nonparotid "acinic cell carcinomas" represent mammary analog secretory carcinomas.

Authors:  Justin A Bishop; Raluca Yonescu; Denise Batista; David W Eisele; William H Westra
Journal:  Am J Surg Pathol       Date:  2013-07       Impact factor: 6.394

4.  Acinic cell carcinoma originating in the nasal cavity.

Authors:  T Hanada; I Moriyama; K Fukami
Journal:  Arch Otorhinolaryngol       Date:  1988

5.  Acinic cell carcinoma of the parotid gland in a child.

Authors:  Takayuki Sato; Shin-Etsu Kamata; Kazuyoshi Kawabata; Tomohiko Nigauri; Hiroki Mitani; Takeshi Beppu; Miki Sato
Journal:  Pediatr Surg Int       Date:  2005-04-02       Impact factor: 1.827

6.  Re-evaluating historic cohort of salivary acinic cell carcinoma with new diagnostic tools.

Authors:  Yu Lei; Simion I Chiosea
Journal:  Head Neck Pathol       Date:  2011-11-30

7.  The embryonal carcinoma of the parotid gland. A rare example of an embryonal tumor.

Authors:  K Donath; G Seifert; J Lentrodt
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

8.  Dedifferentiated acinic cell tumour: the harlequin of salivary gland neoplasms--an unusual variant.

Authors:  Anshu Jain; Kiran Alam; Aroonima Misra; Veena Maheshwari
Journal:  BMJ Case Rep       Date:  2013-05-27

9.  Skull base involvement by acinic cell carcinoma of the parotid gland.

Authors:  Joseph T Breen; Matthew L Carlson; Michael J Link; Eric J Moore; Brian A Neff; Colin L W Driscoll
Journal:  J Neurol Surg B Skull Base       Date:  2012-08-29

Review 10.  Mammary analogue secretory carcinoma: update on a new diagnosis of salivary gland malignancy.

Authors:  Roshan Sethi; Elliott Kozin; Aaron Remenschneider; Josh Meier; Paul VanderLaan; William Faquin; Daniel Deschler; Robert Frankenthaler
Journal:  Laryngoscope       Date:  2013-07-09       Impact factor: 3.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.